As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
17 Analysts have issued a aTyr Pharma, Inc. forecast:
17 Analysts have issued a aTyr Pharma, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 0.19 0.19 |
21%
21%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -79 -79 |
19%
19%
|
|
| EBIT (Operating Income) EBIT | -79 -79 |
16%
16%
|
|
| Net Profit | -75 -75 |
18%
18%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Sanjay Shukla |
| Founded | 2005 |
| Website | www.atyrpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


